To implement these objectives, we investigated biomarkers that reflect the pathophysiology of AD, including tau-related pathology (phosphorylated tau, p-tau), neurodegeneration (total tau, t-tau; MRI measurements), axonal injury (neurofilament light, NFL), synaptic dysfunction (neurogranin), and neuroinflammation (soluble triggering receptor on myeloid cells 2, sTREM2; YKL-40) [13]. The gene discussed is CHI3L1; the disease is Alzheimer disease.